Related Experiment Videos
Tumor necrosis factor as a pharmacological target
Pietro Ghezzi1, Anthony Cerami
1Department of Molecular Biochemistry and Pharmacology, Mario Negri Institute for Pharmacological Research, Milan, Italy.
Methods in Molecular Medicine
|April 6, 2004
Summary
Tumor necrosis factor (TNF), initially known for antitumor effects, was also identified as cachectin, a mediator of cachexia. Subsequent research revealed TNF as a pro-inflammatory cytokine, leading to anti-TNF therapies for inflammatory diseases.
Area of Science:
- Immunology
- Molecular Biology
- Biochemistry
Background:
- Tumor necrosis factor (TNF) was first identified for its antitumor properties.
- TNF was simultaneously discovered to be identical to cachectin, a mediator of cachexia.
- Further research established TNF's role as a key pro-inflammatory cytokine.
Purpose of the Study:
- To summarize the multifaceted roles of TNF.
- To review the development of anti-TNF therapies.
- To outline strategies for TNF inhibition.
Main Methods:
- Literature review of TNF research.
- Analysis of studies on TNF's biological functions.
- Compilation of therapeutic approaches targeting TNF.
Main Results:
- TNF exhibits diverse functions, including antitumor, cachexia-inducing, and pro-inflammatory activities.
- The pro-inflammatory role of TNF has been extensively validated.
- Inhibition of TNF has proven effective in treating specific autoimmune and inflammatory conditions.
Conclusions:
- TNF is a pleiotropic cytokine with significant implications in disease pathogenesis.
- Anti-TNF therapies represent a major advancement in managing inflammatory diseases like rheumatoid arthritis and Crohn's disease.
- Understanding TNF's various roles is crucial for developing targeted therapeutic strategies.